Literature DB >> 36271928

Examining the synergistic effects of a cognitive control video game and a home-based, self-administered non-invasive brain stimulation on alleviating depression: the DiSCoVeR trial protocol.

Esther Dechantsreiter1, Frank Padberg2,3, Alon Morash4, Ulrike Kumpf1, Arthur Nguyen5, Zeno Menestrina5, Fabienne Windel6,7, Gerrit Burkhardt1, Stephan Goerigk1,8,9, Takuya Morishita6,7, Aldo Soldini1, Shira Ahissar10, Tamar Cohen10, Angela Pasqualotto5, Linda Rubene11,12, Liene Konosonoka11,12, Daniel Keeser1,13, Peter Zill1, Razan Assi10, Rémy Gardier14, Roser Viñals14, Jean-Philippe Thiran14,15,16, Ronen Segman4, Yuval Benjamini17, Omer Bonne4, Friedhelm Christoph Hummel6,7,18, Daphne Bavelier5, Elmars Rancans11,12, Mor Nahum10.   

Abstract

Enhanced behavioral interventions are gaining increasing interest as innovative treatment strategies for major depressive disorder (MDD). In this study protocol, we propose to examine the synergistic effects of a self-administered home-treatment, encompassing transcranial direct current stimulation (tDCS) along with a video game based training of attentional control. The study is designed as a two-arm, double-blind, randomized and placebo-controlled multi-center trial (ClinicalTrials.gov: NCT04953208). At three study sites (Israel, Latvia, and Germany), 114 patients with a primary diagnosis of MDD undergo 6 weeks of intervention (30 × 30 min sessions). Patients assigned to the intervention group receive active tDCS (anode F3 and cathode F4; 2 mA intensity) and an action-like video game, while those assigned to the control group receive sham tDCS along with a control video game. An electrode-positioning algorithm is used to standardize tDCS electrode positioning. Participants perform their designated treatment at the clinical center (sessions 1-5) and continue treatment at home under remote supervision (sessions 6-30). The endpoints are feasibility (primary) and safety, treatment efficacy (secondary, i.e., change of Montgomery-Åsberg Depression Rating Scale (MADRS) scores at week six from baseline, clinical response and remission, measures of social, occupational, and psychological functioning, quality of life, and cognitive control (tertiary). Demonstrating the feasibility, safety, and efficacy of this novel combined intervention could expand the range of available treatments for MDD to neuromodulation enhanced interventions providing cost-effective, easily accessible, and low-risk treatment options.ClinicalTrials.gov: NCT04953208.
© 2022. The Author(s).

Entities:  

Keywords:  Cognitive control; Feasibility; Home-treatment; Major depressive disorder; Transcranial direct current stimulation (tDCS); Video game

Year:  2022        PMID: 36271928     DOI: 10.1007/s00406-022-01464-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.760


  82 in total

Review 1.  Antidepressants and body weight: a comprehensive review and meta-analysis.

Authors:  Alessandro Serretti; Laura Mandelli
Journal:  J Clin Psychiatry       Date:  2010-10       Impact factor: 4.384

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

3.  Major Depressive Disorder: New Clinical, Neurobiological, and Treatment Perspectives.

Authors:  David J Kupfer; Ellen Frank; Mary L Phillips
Journal:  Focus (Am Psychiatr Publ)       Date:  2016-04-07

Review 4.  The size and burden of mental disorders and other disorders of the brain in Europe 2010.

Authors:  H U Wittchen; F Jacobi; J Rehm; A Gustavsson; M Svensson; B Jönsson; J Olesen; C Allgulander; J Alonso; C Faravelli; L Fratiglioni; P Jennum; R Lieb; A Maercker; J van Os; M Preisig; L Salvador-Carulla; R Simon; H-C Steinhausen
Journal:  Eur Neuropsychopharmacol       Date:  2011-09       Impact factor: 4.600

5.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

6.  The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses.

Authors:  Stefan G Hofmann; Anu Asnaani; Imke J J Vonk; Alice T Sawyer; Angela Fang
Journal:  Cognit Ther Res       Date:  2012-07-31

7.  Differences and similarities of risk factors for suicidal ideation and attempts among patients with depressive or bipolar disorders.

Authors:  Kari Aaltonen; Petri Näätänen; Martti Heikkinen; Maaria Koivisto; Ilya Baryshnikov; Boris Karpov; Jorma Oksanen; Tarja Melartin; Kirsi Suominen; Grigori Joffe; Tiina Paunio; Erkki Isometsä
Journal:  J Affect Disord       Date:  2016-01-05       Impact factor: 4.839

8.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

9.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

10.  Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report.

Authors:  Taylor A Braund; Gabriel Tillman; Donna M Palmer; Evian Gordon; A John Rush; Anthony W F Harris
Journal:  Transl Psychiatry       Date:  2021-08-04       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.